RL
RPRX icon

Ruffer LLP’s Royalty Pharma RPRX Stock Holding History

Ruffer LLP’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-90,432
Closed -$3.5M – 228
2025
Q4 		$3.5M Sell
90,432
-39,752
-31% -$1.52M 0.16% 73
2025
Q3 		$4.59M Sell
130,184
-47,747
-27% -$1.73M 0.26% 49
2025
Q2 		$6.41M Buy
+177,931
New +$5.89M 0.28% 57

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Ruffer LLP's RPRX Position: Q1 2026 in Review

Ruffer LLP sold out of Royalty Pharma (RPRX) in Q1 2026, closing a stake of 90,432 shares — an estimated $3.5M sold.

Ruffer LLP first reported a position in RPRX in Q2 2025 and held it in 3 quarters. The position peaked at $6.41M in Q2 2025. 591 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Ruffer LLP reported no remaining Royalty Pharma position as of Q1 2026 after selling out during the quarter.
  • Ruffer LLP sold 90,432 Royalty Pharma shares in Q1 2026, an estimated $3.5M.
  • Ruffer LLP first reported a position in Royalty Pharma in Q2 2025 and held it in 3 quarters.
  • Ruffer LLP's Royalty Pharma position peaked at $6.41M in Q2 2025.
  • 591 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Ruffer LLP's 13F filing for Q1 2026, filed 13 May 2026.